GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Abbott Labs

Vir Biotechnology

Market Waits for Major Economic Data This Week.

Market Waits for Major Economic Data This Week

Shares of Vir Biotechnology Inc. VIR, +1.31% gained 9.2% in premarket trading on Monday when the company and GlaxoSmithKline GSK, -0.37% said they had begun dosing patients in the Phase 2/3 clinical study for their experimental COVID-19 antibody treatment.

Vir and GSK start Phase 2/3 trial for experimental COVID-19 treatment

GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage Covid-19 patients.

GlaxoSmithKline and partner Vir join the race to find a coronavirus antibody treatment

GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage COVID-19 patients, entering the race to find a winner in a promising class of antiviral drugs to combat the pandemic.

GSK, partner Vir join race to find COVID-19 antibody treatment

SAN FRANCISCO and LONDON, Aug.  31, 2020  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced that the first patient was dosed last week in a Phase 2/3 study with VIR-7831 (also known as GSK4182136), a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) monoclonal antibody, for the early treatment of COVID-19 in patients who are at high risk of hospitalization.

Vir Biotechnology and GSK Start Phase 2/3 Study of COVID-19 Antibody Treatment

AstraZeneca

BioNTech SE

Heat Biologics

Inovio Pharmaceuticals

Johnson & Johnson

Moderna

Novavax

Pfizer

Sanofi

Vaxart

COVID-19 vaccine stocks have gotten slammed this month.

Has The COVID-19 Vaccine Stock Bubble Burst?

The European Commission lends a nod to Glaxo's (GSK) Blenrep as a monotherapy for patients with relapsed/refractory multiple myeloma, having received at least four previous therapies.

Glaxo Receives EU Approval for Multiple Myeloma Drug Blenrep

GlaxoSmithKline: Quality 5% Dividend Yield Backed By Diversified Asset Portfolio

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing GlaxoSmithKline (GSK) Right Now?

GlaxoSmithKline: Attention Is Now Shifting To Vaccine Manufacturing

Glaxo (GSK) starts dosing with a phase III study on it 5-in-1 meningitis vaccine candidate.

Glaxo Initiates Dosing in Phase III Meningitis Vaccine Study

Eli Lilly

Novartis

AstraZenca, GlaxoSmithKline, Novartis and Eli Lilly are using artificial intelligence systems to help in drug development, decision-making, and more.

These 4 Drugmakers Are Using AI to Improve Their Products. Does It Make Them Better Buys?

The U.S. has doled out billions to develop a vaccine against the coronavirus, locking in a minimum of 800 million doses so far.

The U.S. has already invested billions on potential coronavirus vaccines. Here's where the deals stand

The U.S. Food and Drug Administration on Wednesday approved GlaxoSmithKline's experimental treatment for a common form of blood cancer.

U.S. FDA approves GlaxoSmithKline's blood cancer drug

GlaxoSmithKline plc (NYSE: GSK) announced Wednesday the United States Food and Drug Administration had approved its cancer drug aimed at treating refractory multiple myeloma in adults.

GlaxoSmithKline Gets FDA Approval For Blood Cancer Drug

LONDON--(BUSINESS WIRE)--FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.

FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

MRNA, PFE/BNTX, and AZN are leading the three vaccines in clinical phase 3 trials.

Phase 3 Trials And More: Any COVID-19 Data Is Good Data, Even If It's Bad

These Coronavirus Vaccine Makers Are Winning the Money Game So Far

The U.S. government is supporting development and manufacturing of the coronavirus vaccine in exchange for 100 million doses.

Sanofi and GlaxoSmithKline Snag a $2.1 Billion Contract for Their Coronavirus Vaccine

Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine

CVS Health

Rio Tinto plc Sponsored

Toyota Motor

According to the GuruFocus All-in-One Screener as of July 31, the following guru-held companies have high dividend yields and are trading with low price-earnings ratios.

5 Bargain Stocks With High Dividend Yields

This is the country’s biggest Covid-19 vaccine deal yet.

U.S. To Spend $2.1 Billion On GlaxoSmithKline-Sanofi Covid-19 Vaccine

The feds will give Sanofi and GlaxoSmithKline up to $2.1 billion to churn out a coronavirus vaccine in the Trump administration’s latest and largest bet on an experimental inoculation. More than half the award announced Friday will help the European drugmakers develop and test their vaccine, while the rest will be used to support manufacturing.

Feds pledge up to $2.1B to COVID-19 vaccine from Sanofi, GlaxoSmithKline

These two biotech giants are racing to find a cure for COVID-19. Which one is the better buy?

Better Coronavirus Stock: BioNTech or GlaxoSmithKline?

The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drug makers' testing and manufacturing, the companies said on Friday.

News for GlaxoSmithKline Stock (GSK)